Vaccine distribution help on the way from Google

Google Cloud has launched an AI-backed technology toolkit to help government health personnel direct COVID vaccine doses and other resources where they’re most needed.

Called Intelligent Vaccine Impact, the software suite also has components to help inform, schedule, vaccinate and reassure residents at the local and regional levels.

Google announced the offering this month in a blog post.

For the vaccine distribution component, the company developed a machine learning approach combining AI with epidemiology data and an AI-driven “what if” modeling tool. The latter is designed to prepare health teams for various possible scenarios.

“Using a unique set of Looker dashboards, state epidemiologists and public health professionals can now aggregate the results of these [‘what if’] models … with both public and private datasets to drive better policy decisions,” writes Google Cloud VP Mike Daniels. “Government leaders can then see how the forecasts change in response to policy changes.”

Daniels says Intelligent Vaccine Impact is also intended to broaden vaccine availability while extending “equitable access to those who need it.”

The suite is designed to readily integrate with a wide range of existing technologies, Daniels notes.

Read the rest.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.